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Abstract 
Pathway analysis, broadly defined as a group of methods incorporating a priori biological information 
from public databases, has emerged as a promising approach for analyzing high-dimensional genomic 
data. As part of Genetic Analysis Workshop 18, seven research groups applied pathway analysis 
techniques to whole-genome sequence data from the San Antonio Family Study. Overall, the groups found 
that the potential of pathway analysis to improve detection of causal variants by lowering the multiple-
testing burden and incorporating biologic insight remains largely unrealized. Specifically, there is a lack of 
best practices at each stage of the pathway approach: annotation, analysis, interpretation, and follow-up. 
Annotation of genetic variants is inconsistent across databases, incomplete, and biased toward known 
genes. At the analysis stage insufficient statistical power remains a major challenge. Analyses combining 
rare and common variants may have an inflated type I error rate and may not improve detection of causal 
genes. Inclusion of known causal genes may not improve statistical power, although the fraction of 
explained phenotypic variance may be a more appropriate metric. Interpretation of findings is further 
complicated by evidence in support of interactions between pathways and by the lack of consensus on 
how to best incorporate functional information. Finally, all presented approaches warranted follow-up 
studies, both to reduce the likelihood of false-positive findings and to identify specific causal variants 
within a given pathway. Despite the initial promise of pathway analysis for modeling biological complexity 
of disease phenotypes, many methodological challenges currently remain to be addressed. 
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Pathway analysis, broadly defined as a group of methods incorporating a priori biological 
information from public databases, has emerged as a promising approach for analyzing high-
dimensional genomic data. As part of Genetic Analysis Workshop 18 (GAW18), seven 
research groups applied pathway analysis techniques to whole genome sequence data from 
the San Antonio Family Study. Overall, the groups found that the potential of pathway 
analysis to improve detection of causal variants by lowering the multiple testing burden and 
incorporating biologic insight remains largely unrealized. Specifically, there is a lack of best 
practices at each stage of the pathway approach: annotation, analysis, interpretation, and 
follow-up. Annotation of genetic variants is inconsistent across databases, incomplete, and 
biased towards known genes. At the analysis stage, insufficient statistical power remains a 
major challenge. Analyses combining rare and common variants may have an inflated type 1 
error rate and may not improve detection of causal genes. Inclusion of known causal genes 
may not improve statistical power, although the fraction of explained phenotypic variance 
may be a more appropriate metric. Interpretation of findings is further complicated by 
evidence in support of interactions between pathways as well as the lack of consensus on how 
to best incorporate functional information. Finally, all presented approaches warranted 
follow-up studies, both to reduce the likelihood of false positive findings and to identify 
specific causal variants within a given pathway. Despite the initial promise of pathway 
analysis for modeling biological complexity of disease phenotypes, many methodological 
challenges currently remain to be addressed. 
 




 The advent of next generation sequencing, has produced a wealth of high-resolution 
genomic data at an unprecedented scale. These technologies are enabling novel, 
comprehensive investigations of disease phenotypes, but also creating new challenges for 
analysis and interpretation. Namely, despite the data explosion, we still have relatively low 
power to find genetic associations. Therefore, the central challenge lies in how to best use 
statistical relationships to infer biological mechanisms from detailed sequence information. 
Pathway analysis, broadly defined as a group of statistical methods that exploit a priori 
knowledge of pathways (broadly defined as sets of genes with a known biological 
relationship) stored in public databases such as KEGG (Kanehisa, Goto, Sato, Furumichi, & 
Tanabe, 2012), Gene ontology (T. G. O. Consortium, 2000), Reactome (Croft et al., 2010), 
and others, offers a naturally attractive approach to modeling biological complexity and 
improving detection of statistical associations (Khatri, Sirota, & Butte, 2012). More 
specifically, pathway analysis methods use a variety of different strategies to aggregate or 
interpret individual marker or gene based phenotype association statistics to yield a single 
interpretable test statistic (or p-value) summarizing the strength of evidence of association 
between the pathway and the phenotype. 
Initially based in the context of gene expression arrays, modern pathway analysis 
methods have recently been extended to next-generation sequence data, including structural 
variants and rare genetic polymorphisms (Hu, Xu, Cheng, Xing, & Paterson, 2011; Petersen 
et al., 2011; Tintle et al., 2011; Yang & Gu, 2011). The range of analytical methods that fall 
under the pathway analysis definition is rapidly gaining traction among biomedical 
researchers, evidenced by a more than tenfold rise in PubMed citations since the completion 
of the human genome sequence in 2003 (Ramanan, Shen, Moore, & Saykin, 2012). This rise 
in popularity is not surprising, because pathway analysis holds great promise both from the 
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standpoint of interpretation (by placing findings in context of prior knowledge) as well as 
analysis (reducing the multiple comparisons burden inherent to agnostic genome-wide 
approaches by limiting the number of hypotheses tested to the number of pathways and 
potentially aggregating multiple weaker signals to a stronger signal). However, realizing the 
promise of pathway analysis is not straightforward. Most notably, as for many new 
methodological approaches, pathway analysis suffers from a lack of “gold standards” at every 
step of implementation: annotation, analysis, interpretation, and design of follow-up studies. 
As a result, much of the potential associated with pathway analysis remains untapped. 
Applying biological knowledge-driven methods to whole genome sequence data as 
part of Genetic Analysis Workshop 18 (GAW18) highlighted both the promises and the 
limitations of the pathway approach. In this manuscript, we summarize the results of the work 
carried out by the members of the pathway analysis working group, leveraging the common 
themes to suggest several best practices for future investigations. To that end, we will 
sequentially move through each step of pathway analysis, emphasizing both lessons learned 
and questions that remain open for further research and discussion. 
Methods 
Genotype data and pedigree structure 
GAW18 genotype data was obtained from 959 participants who are part of the San Antonio 
Family Sample of the T2D-Genes project [Cite when paper is available]. Detailed sample 
descriptions are provided elsewhere [Cite when paper is available], but we provide a brief 
overview below. Of the 959 participants, 483 underwent whole genome sequencing using the 
services of Complete Genomics Inc., while the sequence of the remaining 476 individuals was 
imputed based on a combination of (1) pedigree information, (2) genotypes from a ≥500K 
SNP microarray and (3) the completely sequenced 483 individuals, using a novel imputation 
pipeline. The final dataset, consisting of 8,348,674 single nucleotide variants (SNVs) spread 
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across the odd numbered chromosomes and was made available to the workshop for analysis, 
with sample minor allele frequencies (MAF) ranging from 0.1% (singletons; 1/959) to 50%. 
The 959 participants in the sample were derived from 21 distinct multi-generational large 
Mexican-American pedigrees. 
 
Real and simulated phenotypes 
GAW18 participants had the option to analyze either real or simulated hypertension-related 
phenotypes. In particular, real systolic and diastolic blood pressure (SBP and DBP) 
measurements, knowledge of the use of antihypertensive medications, and tobacco smoking 
were provided for each of the 959 individuals in the sample at one to four time points. Sex, 
age and years of examinations were also provided. Blood pressure measurements (SBP and 
DBP measurements), as well as hypertension diagnoses, medication use and tobacco use 
status were also simulated at up to four time points using a set of variants known to be 
associated with BP and a complex genetic disease model (see data description paper (cite 
when available) for details). Two hundred replicates of the simulated phenotype data were 
generated. 
 
Methods used by participants in the pathway group 
The seven contributions to the GAW18 Pathways group used a variety of distinct and 
innovative ways to explore potential associations between phenotypes and multiple SNV 
genotypes, where the SNV genotypes are related due to common pathway annotations (Table 
1). The approaches taken by the group can be broadly categorized into two distinct groupings 
based on how the pathway annotation information is incorporated into statistical analyses. 
The first approach leveraged a priori knowledge of candidate pathways to substantially limit 
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the scope of the analysis, while the second approach, more agnostic in nature, explored large 
sets of pathways for novel relationships with the phenotypes of interest. 
Three groups (Almeida et al., 2013; Aslibekyan et al., 2013; Greco et al., 2013) used 
knowledge of a priori associations in their analyses. Aslibekyan et al. focused on 54,309 
SNVs within 50 kb of 31 genes in pathways known to be associated with hypertension. 
Aslibekyan et al. then used a variance components approach in order to evaluate the 
proportion of variation in real SBP and DBP measurements explained by different subsets of 
the SNVs (e.g., MAF, location).  A similar approach was used by Almeida et al., who used 
simulated SBP and DBP data to evaluate the contributions of KEGG pathways containing 
genes associated with blood pressure, though with the addition of a an empirically estimated 
pathway-specific kinship matrix (PSGRM) to the model. Finally, Greco et al. created 
synthetic sets of genes containing between zero and five genes known to contain 
hypertension-related variants. They then evaluated different approaches for summarizing 
variant-phenotype associations at the pathway level using simulated phenotypes.  
The four remaining groups attempted to find pathways significantly associated with 
the real or simulated phenotypes (Alsulami, Liu, & Beyene, 2013; Dufresne, Oualkacha, 
Forgetta, & Greenwood, 2013; Edwards et al., 2013; Hu & Paterson, 2013). Dufresne et al. 
started by calculating gene-based phenotype associations with DBP, adjusting for the 
complex pedigree structure in a mixed effects model (Oualkacha et al., 2013). They then used 
Cytoscape (Shannon et al., 2003) to determine if any pathways showed an overabundance of 
genes showing at least modest association with DBP (p<0.05). Finally, using a sample of 
unrelated individuals, Dufresne used a partial least squares approach to identify multi-
dimensional linear combinations of SNVs in significant pathways or genes which maximally 
explained changes in DBP over time. A similar approach was taken by Edwards et al., who 
first determined pedigree-adjusted gene-based association statistics for BP phenotypes, 
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followed by analyses to identify pathways showing aggregations of associated genes. In 
addition, Edwards et al. considered the longitudinal nature of the data by defining the 
phenotype of interest as an individual’s average yearly change in SBP or DBP, assuming a 
linear relationship between age and BP. Alsulami et al. first evaluated the evidence for 
association between individual genes on chromosome 3 and BP related phenotypes using a 
variable weight test (VW-TOW) in a set of 129 unrelated individuals. Computation of gene-
based p-values was followed by application of gene set enrichment analysis (GSEA) to 3638 
pathways containing both at least one gene from chromosome 3 as well as 10 genes from the 
odd chromosomes in total. Lastly, Hu and Paterson applied an extended hierarchical 
generalized linear model to determine associations between genes on chromosome 3 and 
simulated blood pressure in a set of 142 unrelated individuals. Hu and Paterson then applied 
GSEA (Michaud et al., 2008) to 531 sets of genes each containing at least five genes on 
chromosome 3. 
Results 
In order to provide a clear and comprehensive overview of the similarities, differences and 
themes in the pathway analysis group, we have organized the results in the general order in 
which pathway analysis is conducted. We focused first on issues of annotation, addressing 
topics like how genes and pathways are identified and what databases are most commonly 
used. Next, we focused on decisions that must be made in the analysis of sequence data using 
pathway approaches including whether the analysis will adjust for covariates, whether rare 
and common variants should be analyzed simultaneously, the effects of non-causal SNPs and 
multiple testing penalties. Third, we discussed issues of interpretation including significance 




Gene boundaries. All pathway group members at GAW18 used bioinformatic knowledge 
about the SNVs to perform multiple aspects of their analyses. In particular, all groups utilized 
information about gene boundaries. Gene start and stop positions are dependent on the choice 
of the reference sequence and may vary among data sets. To address this issue and potentially 
incorporate regulatory sites, the presented analyses extended gene boundaries between 0 and 
50kb upstream of the transcription start site and 0-50kb downstream of the stop codon. All 
groups restricted their analyses to variants in or near coding regions (without giving special 
consideration to splicing variants) rather than the whole genomic interval.  
Pathway annotation. Six of the seven groups utilized external pathway databases containing 
sets of genes known to be functionally related with databases including KEGG (Kyoto 
Encyclopedia of Genes and Genomes (Kanehisa et al., 2012)), GO (Gene Ontology(T. G. O. 
Consortium, 2000)), Reactome (Croft et al., 2010), the GSEA (Gene Set Enrichment 
Analysis) molecular signature database (Subramanian et al., 2005), and Biocarta 
(ww.biocarta.com). The wide variety of pathway databases used helps underscore the 
controversy surrounding the very definition of pathways. Furthermore, despite a large number 
of options for pathway definitions, genome coverage is still low. For example, using 
Cytoscape (Shannon et al., 2003), Dufresne et al. identified pathways for only 35% of the 
candidate genes (120 annotated genes of 600 in the selected list). 
 
Analysis 
Covariate adjustment. With the exception of the analysis by Greco et al., all approaches 
incorporated adjustment for potential confounders such as age or use of anti-hypertension 
medication. Simple covariate adjustment for medication use, however, may have diminished 
statistical power of the BP analyses (Tobin et al., 2005). However, non-genetic covariates 
explained a relatively modest fraction of outcome variance, estimated at 19% by Aslibekyan 
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et al. Models presented by Almeida et al. also included ancestry principal components to 
control for possible population stratification and found them to account for 5% of the total 
variance in BP. Additionally, all papers that analyzed related individuals estimated a kinship 
matrix to account for correlations inherent to family data.   
 
Rare and common variants. All analyses utilized genotypes across the entire allele frequency 
spectrum, either stratifying between rare and common SNVs or considering them 
simultaneously. Hu et al. observed severe inflation of type 1 error rate for analyses combining 
rare and common variants when compared with a stratified analysis using a hierarchical 
generalized linear model. Alsulami et al. addressed this concern by applying differential 
weights to SNVs based on their minor AF (MAF). Although Aslibekyan et al. established that 
rare and very rare variants contribute more to the overall phenotypic variation, the analysis by 
Almeida et al. found that including rare variants did not improve the model’s ability to detect 
causal pathways.  
 
Causal and non-causal variants. Analyses of simulated data highlighted the relevance of 
including causal genes to increase the ability to detect a true effect, i.e. statistical power. 
Specifically, Greco et al. found that for most statistical tests, the number of causal genes in 
the set or the proportion of causal variants did not improve power, but the fraction of 
phenotypic variance explained by causal SNVs did. While the three articles that used 
simulated data (Almeida et al. [2013], Greco et al. [2013], and Hu et al. [2013]) had the 
explicit knowledge of which genes were causal in the pathogenesis of hypertension, the other 
analyses relied on various proxy measures of causality. For example, both Dufresne et al. 
[2013] and Edwards et al. [2013] used only exonic variants, and all other analyses were 
restricted to variants that could be mapped to known genes. Aslibekyan et al. [2013] 
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explicitly compared variance contributions of SNVs within known blood pressure pathway 
genes with those of SNVs located within 50kb upstream of the transcription start site and 
within 50Kb downstream of the stop codon, and found that genic regions played a more 
prominent role in the genetic architecture of hypertension than the flanking regions.  
 
Correcting for multiple testing. An important factor motivating all seven approaches was 
lowering the astronomical multiple testing burden of whole genome sequence analyses by 
incorporating a priori biological knowledge. However, reducing the number of tested 
hypotheses to the number of pre-defined pathways rarely yielded statistically significant 
results, even with relatively liberal correction methods such as the false discovery rate 
(Alsulami et al. [2013], Dufresne et al. [2013], and Hu et al. [2013]). Moreover, Greco et al. 
[2013] reported poor performance of various collapsing techniques in the context of very 
large sets of SNVs, suggesting that the reduction in analytic dimensions was either 
insufficient or masked causal signal. Alternative approaches, such as the one implemented by 
Edwards et al. [2013], effectively ignored the multiple comparison issue by using a two-stage 




Overlap of pathways between phenotypes. Two of the analyses (Dufresne et al. [2013], Hu et 
al. [2013]) found evidence of biological pathway cross-talk, defined as sharing at least one 
functional locus or gene. Hu et al. [2013] observed cross-talk between four pathways 
consistently enriched across adjacent time periods. Similarly, Dufresne et al. [2013] evaluated 
overlapping networks between baseline DBPand the change in DBP over time, and also found 
four common enriched pathways. The evidence in support of cross-talk between biological 
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pathways is further supported by the high degree of correlation between the analyzed 
phenotypes. 
 
Biological narrative vs. data. Many fundamental biological processes such as cell growth or 
adhesion are common to a plethora of phenotypes, which makes it easy to construct a 
plausible biological story out of pathway findings, but can also create challenges in 
interpretation. For example, UBC emerged as a top hub in the analyses presented by Edwards 
et al. [2013] despite not even being included in the input gene lists. UBC encodes ubiquitin, a 
protein that affects a wide range of cellular processes that are not necessarily unique to the 
phenotype of interest. At approximately 6000 bp, UBC is not a particularly large gene (i.e. it 
does not contain many SNVs), nor is it proximal to any of the causal BP variants to suggest 
linkage disequilibrium. In a setting of limited statistical power, driven by a very large number 
of genetic predictors with small effects and a comparatively small number of study 
participants, genes like UBC may represent false positive findings with misleading biological 
plausibility.      
 
Discussion 
The seven members of the pathway analysis group applied a diverse set of novel and existing 
methods of pathway analysis to investigate its utility at finding evidence of plausible 
pathway-phenotype relationships based on next-generation sequencing data. While the groups 
remain generally optimistic about the potential for pathway analysis approaches to the 
analysis of sequence data, performance on GAW18 data was generally poor (likely related, at 
least in part, to the availability of only half of the genome, small sample size, and small 
average effect size), and raised more questions than answers. In particular, the lack of 
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standards or best-practices for pathway analysis remains a significant hurdle when applying 
pathway analysis to single nucleotide variant data.  
Despite its promise of potentially improving statistical power due to a reduction in 
multiple testing and aggregation of independent signals, significant questions about the power 
of pathway analysis in practice still exist. In particular, best practices for extending gene 
boundaries to potentially include transcriptional sites do not exist since transcription factors 
could regulate expression of distantly located target genes due to the chromatin tridimensional 
structure. However, approximately 85% of  active sites are located 2 kb upstream of a 
transcriptional start site (Iwama & Gojobori, 2004) and inclusion of non-causal variants in 
aggregation tests are known to significantly diminish power for most standard approaches 
using either common (Petersen, Alvarez, De Claire, & Tintle, 2013) or rare (Liu, Fast, 
Zawistowski, & Tintle, 2013) variants. Nevertheless, some approaches are more robust to the 
inclusion of non-causal variants than others (Liu et al., 2013; Petersen et al., 2013). Recent 
results assigning function to about 80% of the genome (ENCODE Project Consortium, 2012) 
may substantially change the way we evaluate variants in these regions and define 
biologically meaningful pathways. Further methodological work exploring robust and 
powerful pathway analysis methods is needed particularly in order to limit the impact of non-
causal variants through statistical approaches and bioinformatic prediction.  
 Pathway analysis is also significantly limited by the multitude of options that exist for 
choosing pathways. First, there is the choice between the many existing pathway databases, 
some of them overlapping. Second, the principle of reducing multiple testing penalties by 
testing pathways instead of genes, or even single markers, is predicated on, a priori, 
identification of minimally overlapping pathways which correctly partition the set of all genes 
(or variants) so that causal genes (variants) are in the same pathway, or, if not, the sensitivity 
of statistical approaches to identify a pathway as significant based on a single variant. Stated 
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differently, while multiple testing penalties for testing all m genes (variants) individually are 
substantial when m is large, multiple testing penalties are substantially worse if all possible 
subsets of the m genes (2
m
 possibilities) are tested. Further work is needed to determine 
sensitive and efficient approaches for identifying the subset of the 2
m
 possible pathway sets 
most likely to show strong association with the phenotype. The hierarchical nature of 
pathways are also generally ignored. 
 Compounding the problem even further is the bias towards well-known and 
understood genes in pathway databases. Funding limitations for database curation and a bias 
towards testing well-known genes, instead of investigating higher-risk, but potentially higher 
reward, novel genes, means that only a modest fraction of genes are well-annotated, which 
significantly limits approaches like pathway analysis which require annotation information in 
the analysis.  
 Another issue for pathway analysis is the lack of general approaches which 
incorporate all potential sources of evidence for genotype-phenotype relationships. In 
particular, the GAW18 data is complex due to the inclusion of covariates, family structure, 
and longitudinal, correlated phenotypes. Most groups had to restrict their analyses to certain 
portions of the data in order to use published or novel methods, due to limitations of those 
models which limited their application to unrelated individuals, cross-sectional phenotypes, 
no covariates, etc. As already noted, lack of statistical power is an issue in pathway analysis, 
thus further methodological development is necessary to ensure that all sources of evidence 
can be incorporated in downstream statistical analyses of genetic data.  
Finally, all members of the pathway group framed their results as a starting point for 
further investigations rather than as providing conclusive evidence of causal associations, 
both due to limited statistical power to detect true effects and the imposed restriction to odd-
numbered chromosome variants. As with other high-throughput genomic approaches 
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replication remains the gold standard to establish validity of the findings. In pathway analysis, 
replication efforts are often thwarted by differences in the choice of curated databases with 
only limited overlap between gene sets, as evidenced by the variety of approaches among the 
seven members of the pathway group. Furthermore, because of difficulties in interpretation of 
pathway findings discussed above, such high-level analyses may be followed up by gene-
based or single variant tests to facilitate future research or clinical applications. Finally, 
questions remain about whether a significant pathway association is indicative of a single 
strong variant association, multiple correlated signals, or associations with multiple variants 
of the same outcome (e.g. DBP and SBP), which necessarily impacts choices about how to 
follow-up pathway analysis. 
While numerous questions remain in pathway analysis for sequence data, we are 
encouraged and convinced that the field is worthy of continued methodological development 
for a number of reasons. First, the promise of improved statistical power via multiple testing 
and aggregated signals is too alluring to ignore. This allure is underscored by the potential for 
improved biological interpretation via pathway analysis. Second, the best-practices questions 
for pathways mirror many of those for gene-based tests, thus methodological effort in these 
areas should be synergistic. Third, it is important to note the recent and growing success of 
pathway analysis in the understanding of cancer biology by way of gene expression data. 
While it is possible that the genetic architecture of cancer itself (mutations or deregulation of 
several genes) makes it more conducive to pathway analysis, we believe that many of the 
most debilitating, complex diseases known to have a heritable component (e.g., 
cardiovascular outcomes; psychiatric disorders; diabetes) likely also follow a polygenic 
disease architecture. Finally, combining pathway approaches with transcriptome data may 
enable future studies to generate pathways or gene sets that cover a larger portion of the 
genome and enhance the biological meaning of such findings. 
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Conclusion 
Despite a host of methodological questions about best practices, and the generally 
underwhelming performance of current pathway analysis approaches on GAW18 data, the 




Table 1. Comparison of the GAW18 Gene Pathway working group methods.  







Almeida et al. Simulated Pedigree Variance 
Components 
SOLAR SOLAR KEGG 
Alsulami et al. Real Unrelated VW-TOW VW-TOW GSEA MSigDB 
Aslibekyan et al. Real  Pedigree Variance 
Components 
ASSOC -- Qiagen 
Dufresne et al. Real Both Variance 
Components 
ASKAT Cytoscape Reactome 
Edwards et al. Real Pedigree Linear Model Golden Helix IPA Ingenuity 
Greco et al.  Simulated Pedigree Multiple -- -- Simuled 
Hu and Paterson Simulated Unrelated Linear Model BhGLM GSEA Multiple 
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